<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="66443"><DrugName>solnatide (liquid aerosol inhalation, primary graft dysfunction following lung transplantation), Apeptico/ Mediolanum</DrugName><DrugNamesKey><Name id="43062883">solnatide</Name></DrugNamesKey><DrugSynonyms><Name><Value>peptide TNF alpha modulator (ischemia/reperfusion injury), Apeptico</Value></Name><Name><Value>AP-301-IRI</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>solnatide (liquid aerosol inhalation, primary graft dysfunction following lung transplantation), Apeptico</Value></Name><Name><Value>solnatide</Value><Types><Type>INN</Type></Types></Name><Name><Value>AP-301</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>solnatide (liquid aerosol inhalation, primary graft dysfunction following lung transplantation), Apeptico/ Mediolanum</Value></Name></DrugSynonyms><CompanyOriginator id="1048117">Apeptico Forschung und Entwicklung GmbH</CompanyOriginator><CompaniesPrimary><Company id="18009">Mediolanum Farmaceutici SpA</Company><Company id="1048117">Apeptico Forschung und Entwicklung GmbH</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1048117" type="Company"><TargetEntity id="5035526206" type="organizationId">Apeptico Forschung und Entwicklung GmbH</TargetEntity></SourceEntity><SourceEntity id="18009" type="Company"><TargetEntity id="4295955509" type="organizationId">Mediolanum Farmaceutici SpA</TargetEntity></SourceEntity><SourceEntity id="2891" type="ciIndication"><TargetEntity id="D011546" type="MeSH"/><TargetEntity id="444916" type="ORPHANET"/><TargetEntity id="-736459733" type="omicsDisease"/><TargetEntity id="3839" type="siCondition"/></SourceEntity><SourceEntity id="3141" type="ciIndication"><TargetEntity id="T86.810" type="ICD10"/><TargetEntity id="10051604" type="MEDDRA"/><TargetEntity id="1225" type="siCondition"/></SourceEntity><SourceEntity id="913" type="Action"><TargetEntity id="1955" type="Mechanism">Drugs Acting on Tumor Necrosis Factor (TNF) Receptors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C2">Phase 2 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="2891">Pseudohypoaldosteronism</Indication><Indication id="3141">Lung transplant rejection</Indication></IndicationsPrimary><ActionsSecondary><Action id="913">TNF modulator</Action><Action id="959">Protectant</Action></ActionsSecondary><Technologies><Technology id="616">Inhalant formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="617">Aerosol formulation inhalant</Technology><Technology id="961">Follow on biological product</Technology><Technology id="80">Peptide</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><LastModificationDate>2019-06-29T04:41:12.000Z</LastModificationDate><ChangeDateLast>2016-12-20T00:00:00.000Z</ChangeDateLast><AddedDate>2010-05-12T16:13:41.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1048117" linkType="Company"&gt;Apeptico&lt;/ulink&gt; is developing AP-301-IRI, an orally inhaled formulation of solnatide, a synthetic peptide that corresponds to a structural motif of TNF alpha and presumed to be an analog of AP-301, for the potential prevention and treatment of ischemia/reperfusion injury (primary graft dysfunction) following lung transplantation [&lt;ulink linkID="1077668" linkType="Reference"&gt;1077668&lt;/ulink&gt;], [&lt;ulink linkID="1183000" linkType="Reference"&gt;1183000&lt;/ulink&gt;], [&lt;ulink linkID="1253481" linkType="Reference"&gt;1253481&lt;/ulink&gt;], [&lt;ulink linkID="1319608" linkType="Reference"&gt;1319608&lt;/ulink&gt;], [&lt;ulink linkID="1668903" linkType="Reference"&gt;1668903&lt;/ulink&gt;]; the company is also investigating the drug for the potential treatment of pseudohypoaldosteronism type 1B [&lt;ulink linkID="1715072" linkType="Reference"&gt;1715072&lt;/ulink&gt;].  Europe licensee &lt;ulink linkID="18009" linkType="Company"&gt;Mediolanum Farmaceutici&lt;/ulink&gt;  is also investigating the program [&lt;ulink linkID="1882102" linkType="Reference"&gt;1882102&lt;/ulink&gt;]. A phase II trial for primary graft dysfunction began in  June 2013 and completed in  March 2015  [&lt;ulink linkID="1467734" linkType="Reference"&gt;1467734&lt;/ulink&gt;], [&lt;ulink linkID="1715735" linkType="Reference"&gt;1715735&lt;/ulink&gt;]. In March 2015, topline data were reported [&lt;ulink linkID="1639734" linkType="Reference"&gt;1639734&lt;/ulink&gt;]. In November 2011,  the company was seeking to outlicense the drug [&lt;ulink linkID="1253481" linkType="Reference"&gt;1253481&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In February 2010, the FDA awarded AP-301 Orphan Drug status for the prevention of reperfusion injury in the lung during lung transplant surgery [&lt;ulink linkID="1077707" linkType="Reference"&gt;1077707&lt;/ulink&gt;]. In February 2016, the FDA granted the drug Orphan designation for the treatment of primary graft dysfunction following lung transplantation [&lt;ulink linkID="1733616" linkType="Reference"&gt;1733616&lt;/ulink&gt;]; later that month, the drug was granted Orphan designation by the FDA for the treatment of generalized systemic pseudohypoaldosteronism type 1 (also known as autosomal recessive PHA-I or PHA-IB) [&lt;ulink linkID="1734544" linkType="Reference"&gt;1734544&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In September 2015, the EMA's COMP awarded a positive opinion recommending Orphan status for primary graft dysfunction [&lt;ulink linkID="1693678" linkType="Reference"&gt;1693678&lt;/ulink&gt;]; in October 2015, the EMA granted Orphan Drug Designation to AP-301  for primary graft dysfunction following lung transplantation [&lt;ulink linkID="1702247" linkType="Reference"&gt;1702247&lt;/ulink&gt;]. In November 2015, the drug was recommended for Orphan designation for the treatment of pseudohypoaldosteronism type 1B [&lt;ulink linkID="1715072" linkType="Reference"&gt;1715072&lt;/ulink&gt;]. In December 2015, Orphan Drug status was granted [&lt;ulink linkID="1731095" linkType="Reference"&gt;1731095&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;By June 2015, the company had developed micron sized carrier-free dry powder particles of the drug suitable for oral inhalation via a DPI  [&lt;ulink linkID="1668903" linkType="Reference"&gt;1668903&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2013, the company planned to initiate a phase IIa trial in patients with primary graft dysfunction following lung transplantation in April 2013 [&lt;ulink linkID="1392409" linkType="Reference"&gt;1392409&lt;/ulink&gt;]. In April 2013, the Ethics Committee of the Medical University of Vienna approved the company's application to perform an interventional, randomized, placebo-controlled, parallel-group, phase IIa study in patients with primary graft dysfunction following lung transplantation [&lt;ulink linkID="1429294" linkType="Reference"&gt;1429294&lt;/ulink&gt;]. In June 2013, the pilot phase II trial began to evaluate the effect of orally inhaled AP-301 (&lt;ulink linkID="236328" linkType="Protocol"&gt;NCT02095626&lt;/ulink&gt;; EudraCT2013-000716-21; &lt;ulink linkID="236328" linkType="Protocol"&gt;AP301-III-001&lt;/ulink&gt;), delivered using a nebulizer, on treatment of primary graft dysfunction in mechanically ventilated patients (n = 20) after primary lung transplantation, in Austria [&lt;ulink linkID="1467734" linkType="Reference"&gt;1467734&lt;/ulink&gt;], [&lt;ulink linkID="1715735" linkType="Reference"&gt;1715735&lt;/ulink&gt;]. The trial completed in March 2015 [&lt;ulink linkID="1715735" linkType="Reference"&gt;1715735&lt;/ulink&gt;]. In March 2015, topline data were reported. In the study, AP-301 led to an early resolution of pulmonary edema, significant improvement of gas exchange and normalization of respiratory parameters, shortening of duration of mechanical ventilation and intensive care treatment, and earlier discharge of patients from hospital, when compared to placebo. AP-301-treated patients were discharged 5 days earlier on an average [&lt;ulink linkID="1639734" linkType="Reference"&gt;1639734&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2011, a proof-of-concept phase IIa trial for prevention of ischemia reperfusion injury during lung transplantation was planned [&lt;ulink linkID="1293500" linkType="Reference"&gt;1293500&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2011, the drug was listed as being in phase I [&lt;ulink linkID="1253481" linkType="Reference"&gt;1253481&lt;/ulink&gt;]. In September 2012, data from the phase I study  were presented at the European Respiratory Society Congress in Vienna, Austria. Orally inhaled  AP-301 was safe and well-tolerated by all study subjects [&lt;ulink linkID="1319608" linkType="Reference"&gt;1319608&lt;/ulink&gt;]. In March 2013, data from the single-center double-blind, randomized, placebo-controlled, dose escalation study in healthy male volunteers (n = 48) demonstrated that the drug was safe and well tolerated. Lung function parameters, including FEV1 and PEF, were not affected by the drug and the drug was not accumulated in plasma [&lt;ulink linkID="1392409" linkType="Reference"&gt;1392409&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By  November 2011, the peptide had been validated in mice and pig animal models [&lt;ulink linkID="1253481" linkType="Reference"&gt;1253481&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2010, preclinical data were published. In a rat left lung transplantation model with associated ischemia reperfusion injury, endothelial hyperpermeability and permeability edema which reduced oxygenation, AP-301 improved oxygenation within 24 h of surgery by decreasing production of reactive oxygen species and neutrophil sequestration in the lung [&lt;ulink linkID="1077712" linkType="Reference"&gt;1077712&lt;/ulink&gt;], [&lt;ulink linkID="1078022" linkType="Reference"&gt;1078022&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2010, preclinical studies of AP-301-IRI had been completed [&lt;ulink linkID="1077668" linkType="Reference"&gt;1077668&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1048117">Apeptico Forschung und Entwicklung GmbH</Company><Country id="AT">Austria</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3141">Lung transplant rejection</Indication><StatusDate>2013-06-30T00:00:00.000Z</StatusDate><Source id="1467734" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18009">Mediolanum Farmaceutici SpA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2891">Pseudohypoaldosteronism</Indication><StatusDate>2016-12-02T00:00:00.000Z</StatusDate><Source id="1882102" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1048117">Apeptico Forschung und Entwicklung GmbH</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3141">Lung transplant rejection</Indication><StatusDate>2010-02-10T00:00:00.000Z</StatusDate><Source id="1077707" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1048117">Apeptico Forschung und Entwicklung GmbH</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2891">Pseudohypoaldosteronism</Indication><StatusDate>2016-02-08T00:00:00.000Z</StatusDate><Source id="1734544" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1048117">Apeptico Forschung und Entwicklung GmbH</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2891">Pseudohypoaldosteronism</Indication><StatusDate>2016-12-02T00:00:00.000Z</StatusDate><Source id="1882102" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1048117">Apeptico Forschung und Entwicklung GmbH</Company><Country id="AT">Austria</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3141">Lung transplant rejection</Indication><StatusDate>2010-02-10T00:00:00.000Z</StatusDate><Source id="1077707" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1048117">Apeptico Forschung und Entwicklung GmbH</Company><Country id="AT">Austria</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3141">Lung transplant rejection</Indication><StatusDate>2011-10-24T00:00:00.000Z</StatusDate><Source id="1253481" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1048117">Apeptico Forschung und Entwicklung GmbH</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2891">Pseudohypoaldosteronism</Indication><StatusDate>2015-11-10T00:00:00.000Z</StatusDate><Source id="1715072" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1048117">Apeptico Forschung und Entwicklung GmbH</OwnerCompany><Country id="US">US</Country><Indication id="2891">Pseudohypoaldosteronism</Indication><AwardedIndication>Treatment of generalized systemic pseudohypoaldosteronism type 1 (also known as autosomal recessive PHA-I or PHA-IB)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2016-02-08T00:00:00.000Z</MileStoneDate><Source id="1734544" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1048117">Apeptico Forschung und Entwicklung GmbH</OwnerCompany><Country id="US">US</Country><Indication id="3141">Lung transplant rejection</Indication><AwardedIndication>Treatment of primary graft dysfunction following lung transplantation</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2016-02-04T00:00:00.000Z</MileStoneDate><Source id="1733616" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1048117">Apeptico Forschung und Entwicklung GmbH</OwnerCompany><Country id="EU">EU</Country><Indication id="2891">Pseudohypoaldosteronism</Indication><AwardedIndication>Treatment of pseudohypoaldosteronism type 1B</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2015-12-14T00:00:00.000Z</MileStoneDate><Source id="1731095" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1048117">Apeptico Forschung und Entwicklung GmbH</OwnerCompany><Country id="EU">EU</Country><Indication id="2891">Pseudohypoaldosteronism</Indication><AwardedIndication>Treatment of pseudohypoaldosteronism type 1B</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2015-11-12T00:00:00.000Z</MileStoneDate><Source id="1715072" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1048117">Apeptico Forschung und Entwicklung GmbH</OwnerCompany><Country id="EU">EU</Country><Indication id="3141">Lung transplant rejection</Indication><AwardedIndication>Treatment of primary graft dysfunction following lung transplantation</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2015-10-09T00:00:00.000Z</MileStoneDate><Source id="1702247" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1048117">Apeptico Forschung und Entwicklung GmbH</OwnerCompany><Country id="EU">EU</Country><Indication id="3141">Lung transplant rejection</Indication><AwardedIndication>Treatment of primary graft dysfunction following lung transplantation</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2015-09-03T00:00:00.000Z</MileStoneDate><Source id="1693678" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1048117">Apeptico Forschung und Entwicklung GmbH</OwnerCompany><Country id="US">US</Country><Indication id="3141">Lung transplant rejection</Indication><AwardedIndication>Prevention of ischemia reperfusion injury in the lung during lung tranplantation</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2010-01-29T00:00:00.000Z</MileStoneDate><Source id="1077707" type="PR"/></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1015721">Medical University of Vienna</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1048117">Apeptico Forschung und Entwicklung GmbH</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="1059460">The Austrian Research Promotion Agency FFG</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18009">Mediolanum Farmaceutici SpA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="145846" title="Apeptico to receive funding from the FFG to develop AP-301 for primary graft dysfunction     "/><Deal id="145847" title="Medical University of Vienna to conduct phase IIa study of Apeptico's AP-301 for PGD  "/><Deal id="235595" title="Mediolanum to develop Apeptico's solnatide for pulmonary indications in European markets"/></Deals><PatentFamilies><PatentFamily id="1457477" number="WO-2010099556" title="Method for preventing and treating hyperpermeability"/><PatentFamily id="1683770" number="WO-00009149" title="TNF-derived peptides for use in treating oedema."/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Miraca Holdings Inc" id="1023147"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Apeptico Forschung und Entwicklung GmbH" id="1048117"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Augusta University Research Institute Inc" id="1060619"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>